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Vinyl alcohol (VA) copolymers having fine tunable polarities are 
emerging materials in drug delivery applications. VA copolymers 
rendering well-defined molecular architecture (C/OH ratio = 2, 4, 5 
and 8) were  used as carriers for model drug compound, 
fluorescein exhibited significantly different release characteristics 
depending on the polarity of the polymers. Based on the 
preliminary drug release tests the well-defined VA copolymer 
having C/OH = 5 ratio, poly(vinyl alcohol alt-propenylene) 
copolymer (PVA-5) was selected for nanocomposite synthesis. 
Sorafenib anticancer drug was embedded into PVA-5 (C/OH = 5 
ratio) nanoparticles by nanoprecipitation resulting in 
nanoparticles exhibiting unusual cubic shape. The sorafenib-
loaded nanocomposites showed continous release during a day 
and concentration-dependant cytotoxicity on HT-29 cancer cells. 
This might be interpreted by the sustained release of the drug. 
1. Introduction 
Physiological processes at the molecular level occur at specific 
space and time scales, which are different for every tissue 
predetermining the need for the carriers that allow tunable drug 
release.(Uskoković and Ghosh, 2016) Metals, polymers, ceramics 
and bio-derived materials have been studied and used as medical 
implants.(Prakasam et al., 2017) Such materials can be designed for 
a wide range of biomedical applications, e.g. controlled drug 
delivery devices (Park, 2014) and tissue engineering 
constructs.(Uskoković, 2015) However, these materials should 
possess the ability to be tunable to exhibit complex kinetics of 
therapeutic molecules’ release. Overall, there is a need for the 
development of sensitive and smarter controlled release carriers in 
pharmaceutics.  
Fluorescein (Fig. 1. a) is a chemical dye having several medical 
application. It has been approved by the Food and Drug 
Administration (FDA) of the U.S. Department of Health and Human 
Services since 2006.  
Sorafenib (Fig. 1. b) is a multikinase inhibitor acting at tumor 
angiogenesis and proliferation. It is the exclusive drug 
approved by the FDA against advanced hepatocellular 
carcinoma (HCC) which is the fifth most common malignant 
cancer in the world and the third most frequent trigger of 
cancer-related death.(Hsu et al., 2017) HCC resistance to 
chemotherapeutic agents is especially high. The efficiency of 
sorafenib on tumor elimination is low most likely because of 
drug resistance that has substantially limited the overall 
therapeutic effect of cure. In addition, many patients suffer 
from multiple side effects.(Long et al., 2017) Consequently, the 
development of sustained drug delivery systems to improve 
the bioavailability of sorafenib is an important 
nanopharmaceutical task. 
 
Insert Figure 1 here 
 
Polyvinyl alcohol (PVA) has been widely applied in drug 
delivery application in various forms, such as films,(Stampella 
et al., 2013)
,
(Gan et al., 2016) hydrogels(Sakai et al., 2013), 
nanofibers,(Mahanta and Valiyaveettil, 2012) 
membranes(Manasco et al., 2014) and 
nanocomposites.(George et al., 2012) In composite 
nanoparticles generally hydrophilic drugs are incorporated by 
PVA.(Malarvizhi et al., 2014) In another approach sorafenib, 
the anticancer drug was loaded into PVA-coated 
superparamagnetic iron oxide nanoparticles.(Tom et al., 2018) 
To our knowledge lipophilic PVA has not been used for the 
preparation of nanomedicines. Drug delivery applications can 
benefit from tuning the polarity of PVA copolymers so that 
they can be used in the regulation of controlled drug 
release.(Santos et al., 2018) The polarity of the well-defined 
PVA copolymers can be adjusted by changing the density (i.e. 
C/OH ratio) of the hydroxyl groups along the polymer 
chain.(Su, 2013)
,
(Tuba et al., 2016) 
The polymer hydration properties can be modified by the 
introduction of polar functionalities on the polymer backbone. 
The type and the density of the polar substituents can 
significantly affect the hydration properties and so indirectly 
the embedded drug release rate.(Ghori and Conway, 2015) 
Different polar substitution density allows different water 
mobility thus different drug release characteristics.(Rajabi-
Siahboomi et al., 1996) The substituents of a polymer side 
chain alter its polarity and its melting point. For instance, 
substitutions of the side-chain groups by more polar groups 
result in a reduction in the crystallinity of the polymer, which is 
reflected in a decrease in its melting point. This affects the 
solubility of the polymer in water.(Sarkar and Walker, 1995) 
The number of hydroxyl groups has an impact on the polarity 
of the polymers used as drug carrier which can have a great 
effect on the drug release, as well. 
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PEVA (poly (ethylene-vinyl acetate)) as copolymer of ethylene 
and vinyl acetate is often used in biomedical engineering 
applications as drug delivery matrices. The synthesis of PEVA 
via radical co-polymerization of ethylene with vinyl acetate 
leading to VA copolymer derivatives are well-known.(Okaya, 
1993) Cationic group-transfer polymerization(Mori et al., 1994) 
and palladium-catalyzed ethylene−vinyl acetate 
copolymerization(Ito et al., 2009) are also reported. These 
reactions result in polymers exhibiting randomly distributed 
polar and non-polar dyads. However, reports on the synthesis 
of VA copolymers exhibiting well-defined molecular 
architecture are rare.(Li et al., 2013; Scherman et al., 2002; 
Tuba et al., 2014; Valenti and Wagener, 1998) 
The specific structural characteristics of PVA and VA 
copolymers originating from the sequencing (primary 
structure) of monomeric units, as well as the configurational 
and conformational assembly of the secondary structure, 
affect the drug delivery properties of the carrier material. The 
key aspect in these cases is the relative balance between the 
functional groups (structure, relative concentration, and 
position in the repeating unit) and the overall hydrocarbon 
content of the repeating units, as well as their arrangement in 
homopolymer or copolymer structures.(Pajak et al., 2010) The 
biodegradation of PVA was investigated by several research 
teams using different types of microorganisms over the past 
decades. Pseudomonas microorganisms can degrade the 
polymer by the mechanism through secondary alcohol oxidase 
(SAO) and β-diketone hydrolase (BDH), using specific 
dehydrogenase of PVA observed in Alcaligenes faecalis KK314 
strain.(Chandra and Rustgi, 1998; Chiellini et al., 2003; Pajak et 
al., 2010) The biodegradation of VA copolymers is fostered by 
hydroxyl functionalities of the polymer chain.(Chandra and 
Rustgi, 1998)
, 
(Pajak et al., 2010)  
When the VA-copolymers are synthetized by olefin metathesis 
polymerization the distribution of the OH groups along the 
well-defined VA-copolymer chain can be predetermined unlike 
in case of the random structured PEVA produced by radical 
polymerization. 
Well-defined VA copolymers can be synthesized by ring 
opening metathesis polymerization (ROMP) or acyclic diene 
metathesis polymerization (ADMET) reactions using well-
defined Grubbs, ruthenium-based metathesis catalyst systems 
(Fig. 1. c). ROMP is a chain-growth polymerization process 
where strained cyclic olefins are converted to a polymeric 
material. ROMP reactions are driven by the release of ring 
strain from the monomer(s) (e.g. cycloolefins). ADMET is a 
step-growth polymerization, which involves the elimination of 
small molecules such as ethylene (Fig. 2.).(Sutthasupa et al., 
2010)
, 
(Wagener et al., 2006)  
 
Insert Figure 2 here 
 
In general, molybdenum and tungsten catalysts are relatively 
sensitive to oxygen-containing functional groups including 
alcohols, aldehydes and carboxylic acids. Nevertheless, 
ruthenium metathesis catalysts are rendering high functional 
group tolerances.(Balla et al., 2016) Earlier studies reported 
the ruthenium catalyzed ROMP of hydroxyl functionalized 
cyclooctene resulting in linear hydroxyl-functionalized 
polyoctenamers.(Hillmyer et al., 1995) The synthesis of well-
defined ethylene-vinyl alcohol copolymers was reported by the 
ADMET of two vinyl acetate-containing symmetrical -diene 
monomers (Li et al., 2013) and also introduced primary, 
secondary and tertiary hydroxyl groups in precise intervals into 
the polyolefin chain.(Valenti and Wagener, 1998) By the ROMP 
of a “temporary” strained  cis-4-cyclopentene-1,3-diol 
poly(vinyl alcohol2-alt-methylene) was synthetized under 
forcing conditions.(Scherman et al., 2002)  
In this study well-defined VA-copolymers (Fig. 3.) with fine-
tuneable polarity have been investigated as potential drug 
delivery materials for pre-programmed drug release. VA 
alternating copolymers have been synthetized via olefin 
metathesis reactions by the ROMP of cyclooct-4-ene-1-
ol(Martinez et al., 2014a) and cyclooct-5-ene-1,2-diol 
(Scherman et al., 2005) and ADMET of 1,6-heptadiene-4-ol 
according to standard literature procedures.(Tuba et al., 2014) 
The formed polyolefins were hydrogenated by Pd on carbon 
giving the target VA copolymers in quantitative yield. The 
yields, the polymers’ molecular weights (Mw) and dispersities 
(Ð) summarized in Table 1.  correlate well with the data found 
in the literature.(Tuba et al., 2014)(Martinez et al., 
2014b)(Scherman et al., 2005)  
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Table 1 The GPC analysis (Mw, Ð) and glass transition point Tg values of the PVA 
co-polymers used in controlled drug release experiments
 
*PVA-4 was insoluble in 
THF, no GPC data was obtained. 
**
PVA-5 has crystalline structure, no Tg data was 
obtained 
 
Herein, we report the sustained release of fluorescein and 
sorafenib using well-defined vinyl alcohol copolymers having 
high content of precisely-spaced vinyl alcohol functionalities. 
The fluorescein model compound has been selected for 
preliminary drug release investigations, as its logP value (3.4) is 
similar to that of the sorafenib (3.8). In the preliminary 
experiments fluorescein has been embedded into a series of 
well-defined VA copolymers. Based on the drug release tests, 
the most promising VA copolymer was selected as a 
nanocarrier for sustained sorafenib anticancer drug release. 
VA copolymer-sorafenib nanoparticles have been synthetized 
by nanoprecipitation and subjected to in vitro studies including 
biorelevant drug release test, cellular uptake - and cytotoxicity 
investigations with HT-29 human cancer cell line. 
 
Name
C/O 
ratio
Structure Mw Ð
Tg 
[°C]
PVA 2 2000 - 85
PVA 4 4 -* 1.3 34.4
PVA 5 5 1340 1.3 -**
PVA 8 8 6500 5.7 6.8
  
2. Materials and methods 
 Poly(vinyl alcohol)- (PVA, Mw=30,000-70,000, 87-90% 
hydrolysed), polyoxyethylene sorbitan monooleate- (Tween 
80) and Pluronic F68 emulsifiers; ethanol, acetone, dimethyl 
sulfoxide (DMSO), sodium azide, 1-ethyl-3(3-
dimethylaminopropyl) carbodiimide (EDC), N-
hydroxysuccinimide (NHS) and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), abs. toluene, 
tripropylamine, p-toluenesulfonyl hydrazide, xylenes, BHT, 1,4-
dioxane, TFA, abs. THF,  LiAlH4, abs. diethyl ether, N-
methylmorpholine N-oxide, OsO4, n-hexane, 1,5-
cyclooctadiene, m-chloroperbenzoic acid, 1,6-heptadiene-4-ol, 
palladium on carbon, ethyl vinyl ether and fluorescein sodium 
salt were obtained from Sigma Aldrich, ruthenium catalyst G2 
was from Materia Inc. Sorafenib (free base) was purchased 
from LC Laboratories (US). Cyanine 5 amine was the product of 
Lumiprobe Gmbh (Germany). 
Polymer preparation 
 PVA-4 was synthetized (Fig. 3. a) by the ROMP of acetal-
substituted cyclooctene (COE), where acetal moiety worked as 
a protecting group for 5,6-dihydroxy-COE to increase the 
solubility of the polymer. Acetals were polymerized with G2 
catalysts (Fig. 1. a). Saturation of the polymer backbone, 
followed by deprotection, generated perfectly alternating 
copolymers of vinyl alcohol and ethylene.(Scherman et al., 
2005) 
 PVA-5 was synthetized (Fig. 3. b) by the ADMET of 1,6-
heptadien-4-ol(Tuba et al., 2014) and PVA-8 (Fig. 3. c) by the 
ROMP of cyclooct-4-en-1-ol(Martinez et al., 2014) with G2 
catalyst (Fig. 1. a) in an open vial in a glovebox at ambient 
temperature. Hydrogenation of the resulting polymers were 
performed on palladium on carbon followed by atmospheric 
hydrogen exposure.(Tuba et al., 2014) 
Polymer characterization 
 Routine 
1
H NMR spectra were obtained on a Varian Unity 
INOVA spectrometer operating at an equivalent 
1
H frequency 
of 500 MHz performed at 30 °C.  
 The GPC system was composed of a Waters 515 HPLC 
pump, a Waters 717plus Autosampler, a column system of 2 
Waters Styragel HR columns (HR1 and HR4), a Jetstream 
thermostat and an Agilent Infinity 1260 Differential 
Refractometer detector. Distilled tetrahydrofuran was used as 
eluent with a flow rate was 0.3 mL/min. 
 Thermogravimetric analyses were performed in air 
(50 ml/min) using a Perkin Elmer Pyris 1 Thermogravimetric 
Analyser over a temperature interval 30–600 °C at a heating 
rate of 10 °C min
−1
. 
PVA-fluorescein blend preparation 
 100 mg of polymer was dissolved in 5 ml of the appropriate 
solvent (H2O-PVA, DMSO-PVA-4, MeOH-PVA-5, THF-PVA-8) 
and 5 mg of fluorescein was separately dissolved in 3 ml of 
methanol then the solutions were mixed and stirred together 
for an additional 20 minutes, then the solvent was removed by 
rotavapor. The sample was homogenized by mechanical mixing 
and 10 mg of the resulting solid material was pressed into a 
tablet by direct compression with a PerkinElmer Manual 
Hydraulic Press (5 tons). 
PVA-sorafenib nanoparticle preparation 
 The nanocomposites were formed by nanoprecipitation 
method. During the process 1 ml 10 mg/ml PVA-5 polymer 
dissolved in ethanol and 0.1-0.2 ml 10 mg/ml sorafenib 
solution in aceton were combined, and added (one-shot) to 10 
ml aqueous solution containing PVA, Pluronic F68 or Tween80 
emulsifier. The organic solvent was evaporated by magnetic 
stirring overnight at room temperature and 1 bar. Blank PVA-5 
nanoparticles were prepared similarly using Pluronic F68 
emulsifier, though without sorafenib active agent. To prepare 
sorafenib crystals, the drug was precipitated by the same 
method, but without adding the encapsulating polymer. The 
nanocomposite dispersions were centrifuged by a Hermle Z216 
MK microcentrifuge (Germany) with 15,000 rpm for 20 min, 
washed and redispersed in equal volume of MilliQ water three 
times. 
Characterization of nanoparticles 
 The nanocomposites were imaged with FEI Apreo scanning 
electron microscope (SEM, Thermofisher, USA) at 20 kV. The 
size distribution of the NPs was measured by dynamic light 
scattering method with a Zetasizer Nano ZS (Malvern 
Instruments, Malvern, UK). The particles were characterized by 
the intensity mean diameter and polydispersity index (PDI). 
Zeta potential was measured also by Zetasizer Nano ZS 
(Malvern Instruments, Malvern, UK) after washing and 
redispersion of the nanoparticles in MilliQ water. Thermal 
behavior of the samples was investigated by differential 
scanning calorimetry (DSC) on a Setaram LabsysEvo system. 
The measurements were performed in flowing (50 mL/min) 
high purity argon (99.999%) atmosphere, in 25-300 °C 
temperature range with a scanning rate of 10 °C/min. An 
average of 4-5 mg sample was placed into 100 μL aluminium 
crucible. The measurement results were blank corrected. All 
measurement results were evaluated with Calisto Processing 
(v2.01) software. 
 The encapsulation efficiency was determined after 
dissolving 10% of the prepared and washed nanoparticles in 5 
ml ethanol. The sorafenib concentration was measured by 
HPLC. The chromatography system was Young Lin YL 9100, YL 
Instruments Co., Ltd, South Korea. Chromatographic 
separation was performed on a Zorbax SB-Aq column (150 mm 
× 4.6 mm, 5 μm; Agilent, USA). The mobile phase from time 
zero till 5 min was composed of 70% distilled water (0,025% 
tetrachloroacetic acid) and 30% methanol. The percentage of 
methanol was increased continuously to 100% over 22 min, 
and remained till the time point 30 min. Then, the composition 
was changed back to distilled water (0,025% TFA)–methanol 
(70:30; v:v) within 5 min.  The flow rate was of 1 mL/min 
throughout the 35-min run. Chromatography was performed 
at 30 °C. The absorbance of eluent was measured at a 
wavelength of 255 nm. 
 The concentration of sorafenib was calculated using a 
calibration curve and the encapsulation efficiency was 
calculated as follows: 
 Encapsulation efficiency (%) = (mass of drug in NP / mass of 
total loaded drug) × 100. 
  
In vitro drug release 
 During the pre-programmed drug release experiments 
fluorescein as a model compound was embedded into 
polymers (PVA, PVA-4, PVA-5 and PVA-8) synthesized with 
different polarities, from which fluorescein release was 
monitored by Metertech SP-8001 UV/Visible 
Spectrophotometer at 490 nm.(Doughty, 2010) The 
physiological condition was ensured by phosphate buffered 
saline aqueous solution (50 ml) and incubation at 37 °C, 
continuous shaking at 200 rpm. Samples were taken at the 0
th
, 
5
th
, 10
th
, 20
th
, 30
th
 minutes and 1
st
, 2
nd
, 4
th
, 6
th
 hours of the 
experiments. In each case, the experiments were repeated at 
least three times, the standard deviation of the results was 
well within 10%. 
 The sorafenib-loaded nanocomposite was subjected to 
biorelevant in vitro drug release experiments, that is, after 
their washing, 10 mg nanocomposites were re-suspended in 
15 ml human blood plasma containing 0.03% sodium azide 
bactericide. The NPs in release medium were incubated at 
37°C in G24 Environmental Incubator Shaker (New Brunswick 
Scientific Co. Inc., USA) and shaken by BIO RS-24 Mini-rotator 
(Biosan, Latvia) for 2 days at 700 rpm. At predetermined 
intervals, 0.5 ml of each sample was centrifuged (Hermle Z216 
MK microcentrifuge, Germany) for 20 min at 15,000 rpm, 
washed three times and the gained nanoparticles were 
dissolved in 0.5 ml ethanol. The sorafenib concentration was 
analyzed after HPLC separation as described above. 
Fluorescent dye conjugation 
 For cellular uptake studies the PVA-sorafenib nanoparticles 
were fluorescently labelled in order to make them visible for 
fluorescent activated cell sorting (FACS). Briefly, washed 
nanoparticle (1 mg) dispersion that was resuspended in 0.5 ml 
PBS (pH 7.4) was mixed with 0.1 ml PBS (pH 7.4) containing 10 
mg EDC and 10 mg NHS, and incubated for 60 min at 25°C, 
centrifuged and washed with MilliQ water, and redispersed in 
1.0 ml PBS (pH 7.4). The prepared carbodiimide activated 
nanoparticle dispersion was added to 0.02 ml PBS (pH 7.4) 
solution containing 0.5 mg/ml Cyanine 5 amine fluorescent 
dye, and incubated 1 h at 25°C. Then, the suspension of 
nanoparticles was centrifuged, washed three times and 
redispersed in 1 ml PBS. 
Cell cultures 
 The human cancer cell line HT-29 was grown in RPMI-1640 
medium including 10% fetal calf serum (FCS) and 100 U/ml 
penicillin. The cells were cultured at 37 °C in a humidified 
atmosphere containing 5% CO2. They were trypsinized, 
resuspended and precultured before use. 
In vitro cellular uptake and cytotoxicity studies 
 HT-29 cellular uptake of the nanoparticles was investigated 
by FACS. The cells were cultured in 24-well plates at a cell 
density of 2x10
5
 cells per well at 37 °C for 24 h. Then, 0.1 ml 
nanoparticle was added to each well (3 parallel) and incubated 
for 24 h. The cells cultivated without the nanoparticles were 
used as negative control. The cells were washed by PBS, 
trypsinized and redispersed in PBS containing 2% BSA. Flow 
cytometry was done by a BD FACSAria III Cell sorter (BD 
Biosciences, San Jose, CA, US) at Ex/Em 633/660 nm 
wavelength. Shortly, fluorescent light is emitted by fluorescent 
molecules after excitation by a laser of suitable wavelength. 
Fluorescent light may originate from naturally fluorescing 
materials in the cell, or may originate from fluorescent dyes 
used to label the cell. Using FACS one can physically sort a 
heterogeneous mixture of cells into different populations. 
Usual representation includes the intensity of a single channel 
(horizontal axis) vs number of detected events (vertical axis). 
Histograms can be used to compare a single parameter from 
two different sample populations (e.g. experimental vs. 
control). (see in detail https://www.antibodies-
online.com/resources/17/1247/what-is-flow-cytometry-facs-
analysis/) 
 MTT cytotoxicity assay based on a colorimetric reaction 
was applied to study the effect on viability of HT-29 carcinoma 
cells. Cells were seeded (10000 cells/well) in 96-well plates. 
After 24 h pre-incubation, 200 μl fresh RPMI-1640 medium 
containing 10% FCS and 50 g PVA-sorafenib nanoparticles 
were pipetted to each well (8 parallel). The effect of four 
sorafenib concentration levels (0.5 μg, 1.0 μg, 2.5 μg and 5.0 
μg per well). The positive control samples were also supplied 
by the same amount of free sorafenib in DMSO solution. 
DMSO cytotoxicity (without drugs) was also investigated. After 
12 h, 24 h and 48 h incubation 20 l/well MTT solution (5 mg 
MTT/ml) and 0.2 ml/well culture media were added and the 
incubation took 2 h. The supernatant was removed, and MTT 
lysis solution (DMSO, 1% acetic acid, 10% SDS) was pipetted 
into each well. The cells containing the formed MTT formazan 
crystals were dissolved during 30 min, and, the absorbance of 
cell suspension was measured at 492 nm by a plate reader 
(Robonik Readwell Touch, India). The viability of treated cells 
was related to that of the untreated cells (negative control). 
3. Results and discussion 
In vitro fluorescein release of PVA blends. Preliminary PVA-
fluorescein composite release tests were performed using 
commercially available PVA. These experiments were used as 
etalon tests for the comparison of the fluorescein release 
properties of composites made from polymers with 
preadjusted polarity (various C/OH ratios). 
Fig. 4 shows clearly that polymers with different polarity can 
affect controlled fluorescein release. From the water-soluble 
PVA rapid fluorescein release was observed, as the embedded 
compound was completely dissolved within the first 20 
minutes of the reaction. The experiences demonstrated that 
the greater the C/OH ratio is in the polymer, the slower the 
release of the drug. After 6 hours, the release of the 
fluorescein was only 67%, 51% and 30% for the poly(vinyl 
alcohol alt-ethylene) (PVA-4), poly(vinyl alcohol alt-
propenylene) (PVA-5) and poly(vinyl alcohol alt-hexenylene) 
(PVA-8), respectively. 
 
Insert Figure 4 here 
 
Considering the model drug release experiments, the most 
promising sparingly water-soluble polymer, PVA-5 was 
selected for further investigations. On Fig. 5 the rate of 
fluorescein release is shown in a 6-day time interval. A 
  
relatively intense fluorescein release was observed on the first 
day of the experiment, it reached about 65%. However, the 
process has slowed down and reached only about 85% for the 
6
th
 day of the experiment with the standard deviation of the 
results within 10%. 
 
Insert Figure 5 here 
 
Physical and chemical properties of PVA-sorafenib 
nanoparticles. PVA-5 and PVA-8 were evaluated as having the 
most favourable release kinetics with the model drug, they 
were examined, whether they are suitable for encapsulating 
sorafenib anticancer drug. Meanwhile the PVA-8 showed 
highly non-polar characteristics and was hardly soluble in most 
general solvents, the PVA-5 exhibited sparing solubility in 
water and good solubility in ethanol. In fact, PVA-8 was soluble 
exclusively in hot tetrahydrofuran, and after nanoprecipitation 
in the presence of different emulsifiers, nanoparticles could 
not be prepared, a huge agglomerate formation was observed. 
Hence, PVA-5 was selected to prepare nanotherapeutics by 
nanoprecipitation method (Miladi et al., 2016). Three different 
emulsifiers PVA, Tween 80 and Pluronic F68 were investigated 
during the preparation process. Tween 80 emulsifier in the 
nanoprecipitation process provided nanocomposites with large size, 
while the use of PVA surface active agent resulted in submicron-
sized nanoparticles. Pluronic F68 provided the smallest 
nanocomposites (Fig. 6), thus, it was used to optimize the particle 
preparation.  
 
Insert Figure 6 here 
 
Pluronic F68 concentration was varied in the range of 0.5-5.0% in 
the water phase to find out the optimal emulsifier concentration. 
However, a minimum in the size was found at a surfactant 
concentration of 2% (see Fig. 7 and Table 2) but a small peak in the 
micron size range can be seen in the size distribution (Fig. 7). This is 
also reflected in the PDI value (Table 2) that is higher than 0.2, 
which can be attributed to the agglomeration of the nanoparticles 
or separately precipitated sorafenib particles. The multimodal 
distribution of PVA-5-sorafenib prepared using 5% Pluronic F68 
emulsifier might result from the micelle formation beside the 
mentioned reasons. 
According to Fig. 7 and Table 2 it can be established that 1% 
Pluronic F68 concentration is optimal for the nanocomposite 
preparation in this process. Nanoparticle morphology was 
monitored by scanning electron microscope (SEM) indicating the 
formation of particles mostly of submicron size. This is in 
accordance with the results of measurements achieved by dynamic 
light scattering method. 
 
Insert Figure 7 here 
  
Emulsifier 
concentration (%) 
Intensity mean 
size (d.nm) 
PDI 
 
Zeta potential 
(mV) 
 
0.5 306.1 0.179 - 0.18 
1 271.2 0.142 - 0.45 
2 225.2 0.216 - 0.53 
5 430.0 0.376 - 0.92 
Table 2 Intensity mean diameter, PDI and zeta potential values of PVA-5-sorafenib 
nanoparticles as a function of Pluronic F68 concentration. 
Interestingly, most of the particles exhibited cubic shape (Fig. 8. a) 
which is rather unusual among the polymeric nanoparticles.(El-Enin 
and AL-Shanbari, 2018; Karami and Hamidi, 2016; Salah et al., 2017) 
The precipitation of sorafenib also produced cubic crystals (Fig. 8. 
b), although their size was considerably larger, with an average 
diameter of 1.45 m, while composites containing both the 
polymer and sorafenib had optimally an average size of 225-271 nm 
(Table 2). It means the polymeric nanocomposites also followed the 
shape of the sorafenib crystals, however with substantially reduced 
size.  
 
Insert Figure 8 here 
 
Differential scanning calorimetry (DSC) investigation has been done 
in order to confirm the SEM results. Fig. 9 draws the DSC curves of 
pure-, precipitated sorafenib and PVA-5-sorafenib nanocomposite. 
The endothermic peaks found in all of the three thermograms 
clearly suggest crystal structure of each sample. Pure sorafenib and 
precipitated sorafenib had very similar thermograms, as expected. 
The two overlapping peaks show two different polymorphs: a more 
stable with a high and narrow endotherm and a less stable with a 
wide one. These peaks can be observed also in the PVA-5-sorafenib 
nanocomposite, however, with a substantial shift that verifies the 
formation of nanocrystals, which are visible also in the SEM image 
(Fig. 8).  
 
Insert Figure 9 here 
 
The encapsulation efficiency reached its maximum at 2% Pluronic 
F68 concentration (Table 3), and because the yield of the 
nanoparticles did not change significantly by increasing the 
emulsifier concentration, the loading degree was also the highest 
(12.0 %) at this concentration of surfactant. The ratio of 
encapsulated active agent reduced significantly, when the 
emulsifier concentration was increased to 5 %, which can be 
explained by the elevated solubility of the sorafenib due to the high 
emulsifier concentration. Zeta potential value of PVA-5-sorafenib 
nanoparticles in MilliQ water determined by Zetasizer (Malvern 
Instruments, UK) did not show stabilization by charge of the 
nanoparticles (Table 2). However, the nanoparticle suspensions did 
not show aggregation in the solution of emulsifier during a day or in 
blood plasma during the release study. 
 
Emulsifier 
concentration (%) 
Encapsulation 
efficiency (%) 
Yield (%) Loading degree (%) 
0.5 52.2 70.4 6.8 
1 82.1 69.4 10.7 
2 93.6 71.1 12.0 
  
5 74.7 68.9 9.9 
Table 3 Encapsulation efficiency, yield and loading degree values of PVA-sorafenib 
nanoparticles as a function of Pluronic F68 concentration. 
Biorelevant drug release of PVA-5-sorafenib nanoparticles. 
Sorafenib release of the prepared nanocomposites was investigated 
under biorelevant condition in human blood plasma. The active 
agent was released from the nanocomposites continuously within 
one day (Fig.10.). This is substantially quicker, than that was found 
for fluorescein. Nevertheless, the nanocomposites possess 
significantly higher surface area compared to the PVA blends. 
Moreover, the plasma release medium contains a lot of protein that 
can behave as surfactant, thus via the solubilisation they can 
accelerate the dissolution of sorafenib. Nevertheless, serum 
proteins were proved to be prone to interact with sorafenib.(Shi et 
al., 2015) 
 
Insert Figure 10 here 
 
Carcinoma cellular uptake and cytotoxicity of PVA-5-sorafenib 
nanoparticles. In cellular uptake studies by HT-29 model carcinoma 
cells, during the 24 h incubation time, all of the cells engulfed 
fluorescently labelled sorafenib loaded PVA-5 nanoparticles (Fig. 
11) with a relative count of 16690 ± 1401. Fig. 10 shows the 
histograms of control cells (A) and cells cured with fluorescent 
labelled PVA-5-sorafenib nanoparticles. Comparing the two 
histograms, it can be seen that there is not any overlap between 
the peaks, which means all of the cells contained the fluorescent 
dye after incubation with the labelled nanoparticles. 
 
Insert Figure 11 here 
 
Cytotoxicity tests were performed on HT-29 cells using different 
active agent concentrations. Sorafenib solution was added to the 
cells in DMSO solution, thus the effect of the same concentration 
(0.5% related to the medium volume) of DMSO was also 
investigated and it did not exert significant toxic effect.  
Blank PVA-5 nanoparticles without active agent neither decreased 
the viability of the cells compared to the non-treated cells (negative 
control) (Figure 12). As expected, sorafenib solution triggered 
concentration-dependent cytotoxicity and this was also observed by 
the nanocomposites. However, the viability was reduced to a 
smaller extent, probably due to the prolonged release of the drug. 
48 h incubation with the nanocomposites resulted in the highest 
cytotoxic effect. Although all of the drug was released within one 
day, the burst effect was not too high. Thus, the available drug 
concentration is substantially lower for some hours than in the case 
of sorafenib solution. The rate of cellular uptake must have also 
influenced the cytotoxicity of the nanoparticles. 
 
Insert Figure 12 here 
 
4. Conclusions 
Well-defined vinyl alcohol (VA) copolymer carriers with fine-
tuneable polarity were synthesized via olefin metathesis 
reactions by ROMP and ADMET. By fine tuning the number of 
hydroxyl groups on the polymer chain enabled pre-
programmed drug release of the embedded model drug, 
fluorescein. Most beneficial carrier copolymer, PVA-5 was 
used to incorporate sorafenib anticancer drug by 
nanoprecipitation resulting in the formation of unusual cubic-
shaped nanocomposites. The formed particles released the 
active agent continuously within 24 h. In HT-29 cancer cells 
concentration-related cytotoxicity of the sorafenib-loaded 
nanoparticles was observed. The results can be associated 
with the sustained release of the drug. So far we have 
experienced the formation of cubic-shaped polymeric 
nanocomposites neither in our experiments nor in the 
literature. The main significance of this finding is that the 
encapsulating polymer followed the structure of the drug, 
which is quite unusual, since by polymeric microencapsulation 
typically amorphous composites can be formed. Shape is 
critical parameter influencing cellular uptake and/or the speed 
and site specific drug delivery from the nanoparticles. 
Preferential interaction with targeted proteins can be reached 
on proper shape selection of nanomaterials (Ankamwar, 
2012). This interesting feature of the well-defined PVA 
polymer might be useful in some other application (e.g. 
diagnostic or optical), where the shape gets more role in the 
function of a composite. Thus, in the following studies it is 
important to clarify, whether this surprising phenomenon can 
be realized using this polymer in composite with other 
components. 
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Graphical Abstract 
 
 
 
Sorafenib chemotherapeutic drug VA-
copolymer (C/OH = 5 ratio) nanocomposite 
exhibiting unusual cubic shape shows 
prolonged active agent release.  
 
*Graphical Abstract (for review)
Fig. 1 Structure of fluorescein model (drug compound - a), sorafenib (anticancer drug - b), G-
II catalyst (ruthenium-based metathesis catalyst - c). 
Fig. 2 A generalized example of ring opening metathesis polymerization (ROMP - a) and 
acyclic diene metathesis polymerization (ADMET - b) reactions. 
Fig. 3 Synthesis of well-defined VA-copolymers with different polarities (PVA-4, PVA-5 and 
PVA-8). 
Fig. 4 Rate of fluorescein release from PVA blends as a function of carriers possessing 
different C/O ratio. 
Fig. 5 Rate of fluorescein release by PVA-5 blend (3 independent experiments) in a 6-day 
time interval. 
Fig. 6 Size distribution of PVA-5-sorafenib nanoparticles prepared by PVA, Tween 80 or 
Pluronic F68 emulsifiers. 
Fig. 7 Size distribution of PVA-5-sorafenib nanoparticles prepared by varying concentrations 
(0.5 % - blue line, 1.0 % - yellow dashed line, 2.0 % - green line, 5.0 % - red line) of Pluronic 
F68 emulsifier. 
Fig. 8 Scanning electron microscopic image of PVA-5-sorafenib nanoparticles (A) and 
precipitated sorafenib crystals (B). 
Fig. 9 Differential scanning calorimetry thermograms of pure sorafenib (Sorafenib, green 
line), precipitated sorafenib (SOR-BLANK, red line) and PVA-5-sorafenib nanocomposite 
(SOR-18, blue line). 
Fig. 10 Cumulative sorafenib release of the PVA-5-sorafenib nanocomposites in human blood 
plasma. 
Fig. 11 Fluorescence-activated cell sorting (FACS) diagram of control cells without treatment 
(A) and cells treated with Cyanine5-labelled PVA-5-sorafenib nanocomposites (B). 
Fig. 12 Viability of HT-29 cells by MTT assay due to DMSO, sorafenib in solution (‘SOR’, 
brown columns) and PVA-5-sorafenib nanoparticles (‘PVA-SOR’, green columns) after 12 h, 
24 h and 48 h incubation related to the non-treated (negative control) cells. 
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